Polymeric Organoiron Compounds with Carcinostatic Properties (Branched Hydrazone Linkers)

Bavon Diakanua Nkazi

A dissertation submitted for the fulfillment of the requirements for the degree of Master of Science in the Department of Chemistry / Faculty of Science at the University of the Witwatersrand, Johannesburg.

Supervisor: Professor Eberhard W. Neuse

Johannesburg, 2011.
DECLARATION

I declare that this work is my own, unaided work. It is being submitted for the degree of Master of Science in the Faculty of Science, University of the Witwatersrand, Johannesburg, South Africa. It has not been submitted before for any degree or examination in any other University.

_____________________________________
Bavon Diakanua Nkazi

___________ day of _____________________, 2011.
“An education isn’t how much you have committed to memory, or even how much you know. It’s being able to differentiate between what you do know and what you don’t.”

Anatole France (1844-1924)
IV

ABSTRACT

The insufficient efficaciousness of most currently used anticancer drugs has prompted worldwide efforts to reduce toxic and resistance effects, improve overall bioavailability, and widen the therapeutic window. A particularly promising technology to this end rests on the concept of polymer-drug conjugation, in which the bioactive agent is bound to a meticulously designed macromolecular water-soluble carrier through a biofissionable link.

Drug release in the cancerous cell, strongly pH dependant, proceeds hydrolytically in the acidic intracellular compartment, and this represents an advanced drug delivery method in cancer chemotherapy.

The synthesis of water-soluble macromolecular anticancer drugs composed of a polymeric carrier to which the antineoplastic agents are tied via biodegradable hydrazone links were investigated in this project. Carriers were synthesized essentially by polyaddition and ring-opening methods, and polycondensation process was utilized, refined and routinely used. Polyaspartamides derived from polysuccinimide by aminolytic ring-opening was the parent carrier's structure, allowing for:

a) A non-immunogenic and non-toxic chain construction, which was amenable to biodegradation and ensured catabolic elimination of the duly fragment polymer upon drug release;

b) A highly flexible backbone and the presence of intrachain-type or side group-attached solubilizing groups, which ensured conjugate solution in aqueous media required for rapid dissipation in the central circulation system, even if the conjugated drug itself does not possess water solubility; and;

c) The presence of functional groups as binding sites, represented by the hydrazone entity, which ensured drug attachment and release, was introduced by treatment of polysuccinimide with hydrazine hydrate under specially developed experimental conditions, followed by treatment with selected, functionally active amines providing the aforementioned structural features.
Drug systems were modified so as to contain carbonyl functionality, the crucial reaction site in this hydrazone linking process, and bioactive aldehydes, such as ferrocenylpropenal. A cinnamaldehyde was the primary drug model. In order to illustrate the multidrug-binding capacity of the polyaspartamide type carriers, and at the same time ensuring target-specific drug delivery, folic acid, a potential cell entry facilitator, was co-conjugated to selected polymeric conjugate containing ferrocenylpropenal. Cell carrier and conjugate polymers were purified, fractionated by aqueous phase dialysis in membrane tubing with 12 000 – 14 000 molecular – mass cut - off, and isolated by freeze-drying in ultimate yields of 45 – 80 % as water-soluble materials; and they were structurally characterized by spectroscopic techniques. Inherent viscosities were in the range of 8 – 36 mL g⁻¹. The resulting cinnamaldehyde, curcumin and iron contents of the conjugates were in the range of 4 - 7 %, 10 – 14 % and 1.5 – 2.8 % respectively. In vitro experiments done under buffered solution (performed in polymer laboratory of school of chemistry of the university of the Witwatersrand) showed the released of drugs in cancer cell's pH (pH<7). The results of these tests suggest that in acidic environment PSI-hydrazine carriers drugs systems can release active drug such as ferrocenylpropenal, and on the other hand the polymers drugs systems showed higher stabilities under neutral conditions. Therefore drugs released under pH control can play an important role in future cancer therapy.
This dissertation is dedicated to my wife Bijou Kanabwingi Nkazi, my daughters Elisa Mafwene, Plamedi, Glodi and Blessing Nkazi for their love, understanding, patience and encouragement and support. I could not have coped without them.
VII

ACKNOWLEDGEMENTS

I would like to thank the Almighty God, our creator, without whom I never would have been able to come thus far.

I wish to thank also the following people and organizations that so willingly helped and contributed to this project:

- Professor E.W. Neuse, my supervisor, for his patience, guidance, encouragement, commitment, helpfulness, and support during this throughout this project.
- MRC for financial support of the project.
- The National Research Foundation (NRF), Bradlow Postgraduate Bursary for their financial assistance.
- Mr. Richard Mampa of the School of Chemistry for running all NMR spectra that resulted in this work.
- My colleagues in the Polymer Research Laboratory for sharing their brilliant ideas with me and for their friendship, notably, Hembe Elie Mukaya, Jacques Kayembe, Jacob Masiala, Blessing Aderebrige, and Alain Didier Ilunga Mufula.
- My wife, my daughters and my parents who were helpful in many ways.
- My brothers, sisters and their families Rene Diakanua, Gee Diakanua, Fifi Diakanua, Mimi Diakanua, Bienvenu Kadima, Justine Kimbala, Aime Diakanua, Billy Ilunga, Abe Lunzitisa, Sophie Moza, Kelly Sungamena, Irene Bibomba, Jeannette Diakanua, Fatuma Kanabwingi, Nathan, and Joelle Twite for their love, support, courage, guidance and for their prayers.
VIII

- Prophet Kish and maman Fina, Bishop Timothy, and all members of Full fire Ministries for their love and their prayers.
- My brothers Neddy Lumanu Mulenda and Paul Lumanu Diobo for their love, encouragement and support.
- Kirsti Claassen for her friendship and assistance.
- Maman Kitty Banda for her kindness and assistance.
- Fortune and Aurora for their friendship and support.
- All who pray for me. Your prayers were not valueless.
Table of Contents

Declaration.......................................................................................................................... II
Abstract.............................................................................................................................. IV
Dedication........................................................................................................................ VI
Acknowledgements......................................................................................................... VII
Table of contents.......................................................................................................... VII
List of figures.................................................................................................................. XII
List of schemes............................................................................................................... XII
List of tables................................................................................................................... XIII
List of symbols and abbreviations.................................................................................. XIV

CHAPTER 1- INTRODUCTION ......................................................................................... 1

1.1 Cancer overview........................................................................................................... 2
1.2 Aims of the project...................................................................................................... 4

CHAPTER 2- BACKGROUND AND LITERATURE REVIEW ........................................... 5

2.1 Cancer chemotherapy ............................................................................................... 5
2.1.1 Introduction ........................................................................................................... 5
2.1.2 Cancer chemotherapy ......................................................................................... 5
2.1.3 Categories of chemotherapy drugs ..................................................................... 6
2.1.3.1 Alkylating agents ......................................................................................... 6
2.1.3.2 Antimetabolites ........................................................................................... 7
2.1.3.3 Anthracyclines ............................................................................................ 7
2.1.3.4 Antitumor antibiotics .................................................................................... 7
2.1.3.5 Monoclonal antibodies ................................................................................. 8
2.1.3.6 Platinum drugs .............................................................................................. 8
2.1.3.7 Plant alkaloids ................................................................................................ 9
2.1.3.8 Ferrocenyl drug system ................................................................................ 11
2.1.3.8.1 Ferrocene ferricenium system behavior in the biological environment .... 13
2.1.3.8.2 Ferrocene ferricenium system as candidate anticancer drug model ............ 14
2.2 Polymer-drug conjugation ................................................................................. 16
2.2.1 Conjugation systems ..................................................................................... 16
2.2.1.1 Lysosomotropic conjugates ...................................................................... 18
2.2.1.2 Hydrazine conjugates ............................................................................... 19
2.2.2 Polymers as drug carriers .............................................................................. 19
2.2.2.1 Requirements for polymeric drug carriers ............................................... 20
2.2.1.1.1 Hydrosolubility for intravenous delivery ............................................. 20
2.2.1.1.2 Biodegradability .................................................................................. 20
2.2.1.1.3 Biocompatibility .................................................................................. 21
2.2.1.1.4 Chemical composition ......................................................................... 21
2.2.2.2 Natural polymers as drug carriers ............................................................. 22
2.2.2.2.1 Protein-origin polymers ....................................................................... 22
2.2.2.2.2 Polysaccharidic polymers .................................................................... 23
2.2.4 Synthetic polymers as drug carriers ............................................................... 25
2.2.4.1 Pharmacokinetic of macromolecular prodrugs .......................................... 27
2.2.4.2 Pharmacokinetics of macromolecules at body and organ levels ................ 29
2.2.4.3 Pharmacokinetics of macromolecules at the cellular level ....................... 29
2.2.4.4 Pharmacokinetic benefits of macromolecular prodrugs ............................. 31
2.2.5 Drug systems based on carrier-conjugated ............................................... 31
2.3 Branched hydrazine linkers .............................................................................. 32
2.3.1 Strategy for the synthesis of polymeric carriers containing the hydrazine bridge 33
2.3.2 Hydrazine linker’s stability .......................................................................... 34
2.3.3 Cancer cell’s pH and ferrocenyl hydrazine drugs ......................................... 34
2.3.3.1 pH and cancer cells ................................................................................ 34
2.3.3.2 pH-responsive hydrazine-ferrocenyl conjugates ...................................... 35

CHAPTER 3 - RESULTS AND DISCUSSION ................................................................. 36

3.1 Synthesis of aldehydes and ketones drugs ...................................................... 36
3.1.1 Synthesis of Ferrocenylpropanal .................................................................. 36
3.1.2 Synthesis of acetylferrocene ....................................................................... 37
### 3.2 Synthesis of macromolecular carriers

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.2.1 Introduction</td>
<td>39</td>
</tr>
<tr>
<td>3.2.1 Polyaspartamides</td>
<td>40</td>
</tr>
<tr>
<td>3.2.1.1 Poly-DL-succinimide</td>
<td>41</td>
</tr>
<tr>
<td>3.2.1.2 Poly-α,β-DL-aspartamides</td>
<td>41</td>
</tr>
<tr>
<td>3.2.1.2.1 Polyaspartamide carriers bearing one hydrosolubilizing group</td>
<td>44</td>
</tr>
<tr>
<td>3.2.1.2.2 Terpolyaspartamide carriers</td>
<td>51</td>
</tr>
<tr>
<td>3.2.2 Polymer-drug anchoring</td>
<td>63</td>
</tr>
<tr>
<td>3.2.3 Polymer multidrug conjugation</td>
<td>75</td>
</tr>
<tr>
<td>3.3 Evaluation of the stability of hydrazone linkage at various pH</td>
<td>79</td>
</tr>
<tr>
<td>3.3.1 In vitro stability test at pH 7.4</td>
<td>79</td>
</tr>
<tr>
<td>3.3.2 In vitro released test at pH 6.5</td>
<td>79</td>
</tr>
<tr>
<td>3.3.3 Discussion</td>
<td>82</td>
</tr>
</tbody>
</table>

### 3.3 Discussion

#### CHAPTER 4 - EXPERIMENTAL

<table>
<thead>
<tr>
<th>Subsection</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 General Procedures</td>
<td>83</td>
</tr>
<tr>
<td>4.2 Reagents and Solvents</td>
<td>84</td>
</tr>
<tr>
<td>4.3 Experimental Procedures</td>
<td>84</td>
</tr>
<tr>
<td>4.3.1 Preparation of ferrocenyl drugs</td>
<td>84</td>
</tr>
<tr>
<td>4.3.1.1 Ferrocenylpropenal</td>
<td>84</td>
</tr>
<tr>
<td>4.3.1.2 Acetylferrocene</td>
<td>85</td>
</tr>
<tr>
<td>4.3.2 Preparation of polymeric carriers</td>
<td>85</td>
</tr>
<tr>
<td>4.3.2.1 Poly-DL-succinimide</td>
<td>85</td>
</tr>
<tr>
<td>4.3.2.2 Synthesis of copolyaspartamides</td>
<td>86</td>
</tr>
<tr>
<td>4.3.2.3 Synthesis of terpolyaspartamides</td>
<td>91</td>
</tr>
<tr>
<td>4.3.3 Preparation of polymeric conjugates</td>
<td>99</td>
</tr>
<tr>
<td>4.3.3.1 Polyaspartamides-ferrocenyl anchoring</td>
<td>99</td>
</tr>
<tr>
<td>4.3.3.2 Polyaspartamides multidrug conjugation</td>
<td>101</td>
</tr>
</tbody>
</table>
LISTS OF FIGURES

Figure 1.1: Cancer cells ......................................................................................................... 1
Figure 1.2: Cell cycle phases ................................................................................................. 3
Figure 2.1: Mechanism of action for anticancer drugs.......................................................... 10
Figure 2.2: Ferroquine and ferrocifen structures ................................................................. 12
Figure 2.3: Pathophysiology of tumor tissue ......................................................................... 18
Figure 2.4: Ringsdorf model of synthetic polymer drugs ...................................................... 26
Figure 2.5: Examples of targets, barriers and strategies for intracellular drug delivery 28
Figure 2.6: Schematic representation of the intracellular fate of macromolecule
drug conjugate after endocytosis ......................................................................................... 31
Figure 2.7: Formation of hydrazone bridge ....................................................................... 33
Figure 2.8: pH control of hydrazone-ferrocenyl conjugates ............................................... 35
Figure 3.1: Models of hydrazone-conjugates ..................................................................... 64
Figure 3.2: Multidrugs conjugation ..................................................................................... 75
Figure 3.3: Percentage of hydrazone formation at pH values from 3.5 to 7 ................. 80
Figure 3.4: Fcp concentrations against times at neutral and acid pH ............................. 80
Figure 3.5: Fcp concentrations against times at different pH ........................................... 81
Figure 3.6: Released of aldehydes and ketones drugs at pH 6.5 ....................................... 81
## Lists of Schemes

**Scheme 2.1:** Reversible oxidation/reduction .................................................. 12  
**Scheme 2.2:** Biological interactions involving the ferrocene-ferricenium system ....... 14  
**Scheme 2.3:** Ferricenium reduction by NADH .................................................. 14  
**Scheme 2.4:** Flow chart describing drug conjugate pharmacokinetics .................. 27  
**Scheme 2.5:** Interaction between hydrazine and aldehyde groups ....................... 34  
**Scheme 3.1:** Synthesis of 3-ferrocenylpropenal ............................................ 36  
**Scheme 3.2:** Synthesis of acetylferrocene ..................................................... 37  
**Scheme 3.3:** Basic carrier model ..................................................................... 40  
**Scheme 3.4:** Polycondensation of DL-aspartic acid ......................................... 41  
**Scheme 3.5:** Reaction scheme of formation of homopoly(α, β-DL-aspartamides) ...... 42  
**Scheme 3.6:** Aminolytic ring opening reaction leading to the formation of copolyaspartamide .......................................................................................... 42  
**Scheme 3.7:** Synthesis of copolyaspartamides carriers 2a (80) – 2f (80) .............. 46  
**Scheme 3.8:** Synthesis of copolyaspartamides carriers 2a (80) – 2f (80) .............. 47  
**Scheme 3.9:** Synthesis of terpolyaspartamides carriers 3a (50) – 3e (60) .......... 52  
**Scheme 3.10:** Synthesis of terpolyaspartamides carriers 3a (60) – 3e (60) .......... 53  
**Scheme 3.11:** Synthesis of terpolyaspartamides carriers 4a (60) – 4e (60) .......... 58  
**Scheme 3.12:** Synthesis of terpolyaspartamides carriers 4a (50) – 4e (50) .......... 59  
**Scheme 3.13:** Synthesis of conjugates 2a (80)-Fcp – 2f (90)-Fcp ......................... 67  
**Scheme 3.14:** Synthesis of conjugates 3a (60)-Fcp – 3e (50)-Fcp ......................... 68  
**Scheme 3.15:** Synthesis of conjugates 4a (60)-Fcp – 4e (50)-Fcp ......................... 69  
**Scheme 3.16:** Synthesis of conjugates with Fca, Fcc and Cyn ................................ 70  
**Scheme 3.17:** Synthesis of co-conjugates 2a (80)- FA-Fcp, 2a (90)-FA-Fcp and 4c (60)- Cur- Fcp .................................................................................................................. 76
LISTS OF TABLES

Table 3.1: Summary of experimental data for ferrocenyl drugs .................................................. 38
Table 3.2: $^1$H NMR of ferrocenyl drugs .................................................................................... 38
Table 3.3: Summary of experimental data for copolyaspartamide carriers .............................. 48
Table 3.4: $^1$H NMR of copolyaspartamide 2a (80) to 2f (90) ..................................................... 49
Table 3.5: Summary of experimental data for terpolyaspartamide carriers 3 ......................... 54
Table 3.6: $^1$H NMR of terpolyaspartamides 3a (50) to 3f (60) .................................................. 55
Table 3.7: Summary of experimental data for terpolyaspartamide carriers 4 ......................... 60
Table 3.8: $^1$H NMR of terpolyaspartamides 4a (50) to 4f (60) .................................................. 61
Table 3.9: Preparative and analytical data of drug-conjugates .................................................... 71
Table 3.10: $^1$H NMR of drug-conjugates .................................................................................... 73
Table 3.11: Analytical data of drug-conjugates ........................................................................... 77
Table 3.12: $^1$H NMR for selected PAsA co-conjugates ...................................................... 78
LISTS OF ABBREVIATIONS

AEE: 2-(2-Aminoethoxy)ethanol
ATP: 4-amino-2,2,6,6-tetramethylpiperidine
Boc: tert-butoxycarbonyl
Calcd: Calculated
Cur: Curcumin
Cyn: Cinnamaldehyde
DCC: Dicyclocexylcarbodiimide
DEEA: 2-(diethylamino)ethylamine
DMEA: 2-(dimethylamino)ethylamine
DEP: 3-(diethylamino)propylamine
DET: Diethylenetriamine
DHFR: Dihydrofolate reductase
DMF: N,N-Dimethylformamide
DMP: 3-(N,N-Dimethylamino)propylamine
DMSO: Dimethyl sulfoxide
DNA: Deoxyribonucleic acid
EPR: Enhanced permeability and retention
EtAc: Ethyl acetate
FA: Folic acid
FAO: Food and agriculture organization
FDA: Food and Drug Administration
Fca: Acetylferrocene
Fcc: Ferrocencarboxyaldehyde
Fcp: Ferrocenylpropenal
Fcp': Ferrocenylpropenal (with different feeding ratio than Fcp)
FR: Folate receptor
GPC: Gel permeation chromatography
GSH: Glutathione
Hex: Hexane
Hy: Hydrazine
Inh: Inherent
IR: Infrared
MTX: Methotrexate
NMP: N-Methylpyrrolidone
NMR: Nuclear magnetic resonance
PAA: Poly(amidoamine)
PAsA: polyaspartamide
PSI: polysuccinimide
RFC: Reduced folate carrier
RNA: Ribonucleic acid
RT: Room temperature
SOD: Superoxide dismutase
UV-Vis: Ultraviolet-visible
WHO: World health organization